Filing Flows › Starling Oncology (STLN) › Q2 2026 › vs Q2 2025
Starling Oncology (STLN) Q2 2026 vs Q2 2025 (year over year)
Starling Oncology's revenue rose $41.5M (+35%) from $120M in Q2 2025 to $161M in Q2 2026. The biggest changes: Specialty Pharmacy +$36.0M (+58%); Patient services +$2.9M (+5%); Clinical trials & other +$2.5M (+188%).
Starling Oncology, Q2 2026: revenue $161M (+35% year over year), operating margin -2.9%, net loss $9.8M, operating cash flow $11.9M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 6.8% | -9.5% | +16.4 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| FFS revenue | $30.9M | $37.0M | −$6.2M | -17% |
| Capitated revenue | $28.0M | $18.8M | $9.1M | +48% |
| Patient services | $58.8M | $55.9M | $2.9M | +5% |
| Specialty Pharmacy | $98.6M | $62.6M | $36.0M | +58% |
| Clinical trials & other | $3.8M | $1.3M | $2.5M | +188% |
| Revenue | $161M | $120M | $41.5M | +35% |
| Net loss | $9.8M | $17.0M | −$7.2M | -42% |
| Costs & expenses | $171M | $137M | $34.1M | +25% |
| Operating costs | $166M | $131M | $34.9M | +27% |
| Interest & other, net | $5.2M | $5.9M | −$756K | -13% |
| SG&A | $29.9M | $26.9M | $3.0M | +11% |
| Other operating costs | $136M | $104M | $31.8M | +31% |
| Operating cash sources | $21.7M | $6.8M | $14.9M | +219% |
| Depreciation & amortization | $1.8M | $1.8M | $33K | +2% |
| Share-based compensation | $1.1M | $752K | $318K | +42% |
| Working capital & other | $18.8M | $4.2M | $14.6M | +343% |
| Net loss absorbed | $9.8M | $17.0M | −$7.2M | -42% |
| Operating cash flow | $11.9M | −$10.2M | $22.1M | — |
| Free cash flow (OCF − capex) | $11.0M | −$11.4M | $22.4M | — |
| Capital expenditures | $908K | $1.2M | −$300K | -25% |
Questions
How much did Starling Oncology's revenue grow year over year in Q2 2026?
Starling Oncology's revenue rose $41.5M (+35%) from $120M in Q2 2025 to $161M in Q2 2026.
What drove Starling Oncology's revenue change in Q2 2026?
Specialty Pharmacy +$36.0M (+58%); Patient services +$2.9M (+5%); Clinical trials & other +$2.5M (+188%).